GYKI 52466 has positive modulatory effects on AMPA receptors

This publication has 16 references indexed in Scilit:

• Effects of the Potent Ampakine CX614 on Hippocampal and Recombinant AMPA Receptors: Interactions with Cyclothiazide and GYKI 52466
  Molecular Pharmacology, 2000
• Allosteric regulation of α-amino-3-hydroxy-5-methyl-4-isoxazole-propionate receptors by thiocyanate and cyclothiazide at a common modulatory site distinct from that of 2,3-benzodiazepines
  Neuroscience, 1998
• Effects of a centrally active benzoylpiperidine drug on α-amino-3-hydroxy-5-methyl-4-isoxalepropionic acid receptor kinetics
  Neuroscience, 1996
• Selective antagonism of AMPA receptors unmasks kainate receptor-mediated responses in hippocampal neurons
  Neuron, 1995
• Comparative patch clamp studies on the kinetics and selectivity of glutamate receptor antagonism by 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX) and 1-(4-amino-phenyl)-4-methyl-7,8-methylendioxyl-5H-2,3-benzodiazepine (GYKI 52466)
  Neuropharmacology, 1994
• A centrally active drug that modulates AMPA receptor gated currents
  Brain Research, 1994
• Cyclothiazide reverses AMPA receptor antagonism of the 2,3-benzodiazepine, GYKI 53655
  European Journal of Pharmacology: Molecular Pharmacology, 1993
• GYKI 52466, a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses
  Neuron, 1993
• Action of brief pulses of glutamate on AMPA/kainate receptors in patches from different neurones of rat hippocampal slices.
  The Journal of Physiology, 1992
• Glutamate-operated channels: Developmentally early and mature forms arise by alternative splicing
  Neuron, 1991